EP0920312A4 - Apoptose induzioerende adamantyl-derivate und deren verwendung als antikrebsmittel - Google Patents

Apoptose induzioerende adamantyl-derivate und deren verwendung als antikrebsmittel

Info

Publication number: EP0920312A4
Authority: EP; European Patent Office
Prior art keywords: cancer; adamantyl; pct; sec; useful
Prior art date: 1996-07-08
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

EP97933256A

Other languages

English (en)

French (fr)

Other versions

EP0920312B1 (de

EP0920312A1 (de

Inventor

Magnus Pfahl

Xian-Ping Lu

Darryl Rideout

Hongyue Zhang

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Galderma Research and Development SNC

Original Assignee

Galderma Research and Development SNC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-07-08

Filing date

1997-07-08

Publication date

2000-11-02

1997-07-08 Application filed by Galderma Research and Development SNC filed Critical Galderma Research and Development SNC

1997-07-08 Priority to DK97933256T priority Critical patent/DK0920312T3/da

1999-06-09 Publication of EP0920312A1 publication Critical patent/EP0920312A1/de

2000-11-02 Publication of EP0920312A4 publication Critical patent/EP0920312A4/de

2004-12-08 Application granted granted Critical

2004-12-08 Publication of EP0920312B1 publication Critical patent/EP0920312B1/de

2017-07-08 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Physical Education & Sports Medicine (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Emergency Medicine (AREA)
Cardiology (AREA)
Dermatology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Heart & Thoracic Surgery (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Cosmetics (AREA)
Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
Saccharide Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

EP97933256A 1996-07-08 1997-07-08 Apoptose induzierende adamantyl-derivate und deren verwendung als antikrebsmittel Expired - Lifetime EP0920312B1 (de)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
DK97933256T DK0920312T3 (da)	1996-07-08	1997-07-08	Apoptoseinducerende adamantylderivater og deres anvendelse som anticancermidler

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US2128596P	1996-07-08	1996-07-08
US21285P		1996-07-08
PCT/US1997/011564 WO1998001132A1 (en)	1996-07-08	1997-07-08	Apoptosis inducing adamantyl derivatives and their usage as anti-cancer agents

Publications (3)

Publication Number	Publication Date
EP0920312A1 EP0920312A1 (de)	1999-06-09
EP0920312A4 true EP0920312A4 (de)	2000-11-02
EP0920312B1 EP0920312B1 (de)	2004-12-08

Family

ID=21803357

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP97933256A Expired - Lifetime EP0920312B1 (de)	1996-07-08	1997-07-08	Apoptose induzierende adamantyl-derivate und deren verwendung als antikrebsmittel

Country Status (21)

Country	Link
US (1)	US6127415A (de)
EP (1)	EP0920312B1 (de)
JP (1)	JP2000515506A (de)
KR (1)	KR20000023626A (de)
CN (1)	CN1279902C (de)
AT (1)	ATE284213T1 (de)
AU (1)	AU719311B2 (de)
BG (1)	BG103152A (de)
BR (1)	BR9710255A (de)
CA (1)	CA2259936C (de)
CZ (1)	CZ3499A3 (de)
DE (1)	DE69731885T2 (de)
ES (1)	ES2231877T3 (de)
HU (1)	HUP9903834A3 (de)
IL (1)	IL127946A0 (de)
NO (1)	NO990066L (de)
NZ (1)	NZ333800A (de)
PT (1)	PT920312E (de)
RU (1)	RU2209626C2 (de)
TR (1)	TR199900684T2 (de)
WO (1)	WO1998001132A1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6462064B1 (en) *	1996-07-08	2002-10-08	Galderma Research & Development S.N.C.	Apoptosis inducing adamantyl derivatives and their usage as anti-cancer agents, especially for cervical cancers and dysplasias
FR2757852B1 (fr)	1996-12-31	1999-02-19	Cird Galderma	Composes stilbeniques a groupement adamantyl, compositions les contenant et utilisations
FR2759292B1 (fr) *	1997-02-10	2000-08-11	Cird Galderma	Utilisation de retinoides en tant qu'agents induisant la pigmentation
FR2779723B1 (fr) *	1998-06-12	2000-07-13	Cird Galderma	Composes biaryles heterocycliques aromatiques, compositions pharmaceutiques et cosmetiques les contenant et utilisations
NZ517993A (en)	1999-08-31	2004-03-26	Incyte San Diego Inc	Benzylidene-thiazolidinediones and analogues and their use in the treatment of diabetes
IL157740A0 (en)	2001-03-07	2004-03-28	Incyte San Diego Inc	Heterocyclic derivatives and pharmaceutical compositions containing the same
US7265139B2 (en) *	2001-03-08	2007-09-04	Incyte San Diego Inc.	RXR activating molecules
CA2340824A1 (en) *	2001-03-14	2002-09-14	Ibm Canada Limited-Ibm Canada Limitee	Method and system for application behavior analysis
US6613534B2 (en)	2001-03-20	2003-09-02	Wake Forest University Health Sciences	MAP-2 as a determinant of metastatic potential
ITRM20010464A1 (it) *	2001-07-31	2003-01-31	Sigma Tau Ind Farmaceuti	Derivati retinoidi ad attivita' antiangiogenica, antitumorale e pro-apoptotica.
WO2003016267A1 (en) *	2001-08-17	2003-02-27	Incyte San Diego Incorporated	Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia
RU2275367C2 (ru) *	2001-10-31	2006-04-27	Ф.Хоффманн-Ля Рош Аг	Ретиноидные соединения, способ их получения (варианты), фармацевтическая композиция на их основе и способ лечения обструктивного заболевания воздушных путей, рака или дерматологического нарушения или расстройства
AU2002352706A1 (en) *	2001-11-15	2003-06-10	Maxia Pharmaceuticals, Inc.	N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders, cancer, and other diseases
EP1456165A1 (de) *	2001-11-30	2004-09-15	The Burnham Institute	Induktion von apoptose in krebszellen
US7196108B2 (en) *	2002-03-08	2007-03-27	Incyte San Diego Inc.	Bicyclic heterocycles for the treatment of diabetes and other diseases
US7102000B2 (en) *	2002-03-08	2006-09-05	Incyte San Diego Inc.	Heterocyclic amide derivatives for the treatment of diabetes and other diseases
US7019017B2 (en) *	2002-05-14	2006-03-28	Baylor College Of Medicine	Small molecule inhibitors of HER2 expression
US7449480B2 (en) *	2002-05-14	2008-11-11	Baylor College Of Medicine	Small molecule inhibitors of HER2 expression
US20040156799A1 (en) *	2002-06-04	2004-08-12	Zigang Dong	Cancer treatment method and compositions
US6864264B1 (en)	2002-08-20	2005-03-08	Gloria L. Anderson	1-adamantyl chalcones for the treatment of proliferative disorders
US20050014767A1 (en) *	2003-01-29	2005-01-20	Magnus Pfahl	Benzoxazole, benzothiazole, and benzimidazole derivatives for the treatment of cancer and other diseases
CN1774246A (zh) *	2003-04-18	2006-05-17	因齐特圣迭戈公司	用于治疗代谢失调、癌症和其它疾病的取代异色满化合物
RU2257894C1 (ru) *	2003-12-03	2005-08-10	Государственный научный центр-Институт биофизики	Противоопухолевое средство бензамид
WO2007063522A1 (en) *	2005-12-02	2007-06-07	Finorga Sas	Process for the preparation of aromatic derivatives of 1-adamantane
DE602007006663D1 (de) *	2006-06-12	2010-07-01	Univ Ramot	Verfahren zur behandlung von krebs
CN113636966B (zh)	2007-01-15	2024-01-12	于崇曦	维生素a酸类和类维生素a酸化合物的前药
EP2520561B1 (de)	2007-06-08	2016-02-10	MannKind Corporation	IRE-1a-Inhibitoren
RU2360692C1 (ru) *	2007-12-21	2009-07-10	Тихоокеанский Институт Биоорганической Химии Дальневосточного Отделения Российской Академии Наук (Тибох Дво Ран)	Средство, стимулирующее апоптоз клеток лейкемии человека
CN102241678B (zh) *	2011-04-26	2014-10-29	辽宁利锋科技开发有限公司	含有脂环结构化合物的抗肿瘤作用与应用
KR101604053B1 (ko) *	2011-08-05	2016-03-16	(주)아모레퍼시픽	신규 벤조산아미드 화합물
CN103936770B (zh) *	2014-04-11	2016-06-01	安徽师范大学	金刚烷基吡啶酰胺配合物、中间体及其制备方法和应用
CN103923107B (zh) *	2014-04-11	2016-06-01	安徽师范大学	金刚烷基吡啶配合物、中间体及其制备方法和应用
CN103936771B (zh) *	2014-04-11	2016-06-01	安徽师范大学	金刚烷基吡啶甲酰胺配合物、中间体及其制备方法和应用
WO2017053778A1 (en)	2015-09-25	2017-03-30	Fuchs Helen Burgwyn	Antibacterial and antifungal compounds
US20170181988A1 (en) *	2015-12-23	2017-06-29	Cipla Limited	Methods for the treatment of bladder cancer
EP3301085A1 (de) *	2016-09-29	2018-04-04	Biogem S.Ca.R.L.	Retinoidderivate mit antitumorwirkung
US11278025B2 (en)	2017-05-17	2022-03-22	The General Hospital Corporation	Antibiotic compounds
IT201900003343A1 (it)	2019-03-07	2020-09-07	Special Product’S Line S P A	Derivati fenolici per uso come antimicrobici, antibatterici, battericidi
EP3937943A4 (de)	2019-03-15	2022-12-07	The General Hospital Corporation	Neue kleinmolekülige inhibitoren der tead-transkriptionsfaktoren
CN112341406B (zh) *	2020-11-18	2023-02-10	韶远科技（上海)有限公司	反式-4-[4-(3-甲氧基-4-硝基苯基)-1-哌嗪基]金刚烷-1-醇合成方法
IT202000029882A1 (it)	2020-12-04	2022-06-04	Special Product’S Line S P A	Derivati fenolici per uso come antimicrobici, antibatterici, battericidi
IT202000029912A1 (it)	2020-12-04	2022-06-04	Special Product’S Line S P A	Derivati fenolici per uso come antimicrobici, antibatterici, battericidi
IT202000029906A1 (it)	2020-12-04	2022-06-04	Special Product’S Line S P A	Derivati fenolici per uso come antimicrobici, antibatterici, battericidi.
WO2022229017A1 (en)	2021-04-27	2022-11-03	Biogem S.C.A R.L.	Adamantyl retinoid derivative with anticancer activity

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1997003682A1 (en) *	1995-07-17	1997-02-06	Centre International De Recherches Dermatologiques C.I.R.D. Galderma	Method for treating cancers using 6-[3-[1-adamantyl]-4-hydroxyphenyl]

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HU182048B (en) *	1978-04-14	1983-12-28	Sumitomo Chemical Co	Process for preparing brendane derivatives and brendane analogues
DE3026579A1 (de) *	1980-07-14	1982-02-11	Kali-Chemie Pharma Gmbh, 3000 Hannover	2,9-dioxatricyclo (4,3,1,o(pfeil hoch)3,7(pfeil hoch)) decane
LU85544A1 (fr) *	1984-09-19	1986-04-03	Cird	Derives heterocycliques aromatiques,leur procede de preparation et leur application dans les domaines therapeutique et cosmetique
LU85849A1 (fr) *	1985-04-11	1986-11-05	Cird	Derives benzonaphtaleniques,leur procede de preparation et leur application dans les domaines pharmaceutiques et cosmetiques
US5098929A (en) *	1985-07-30	1992-03-24	The Wellcome Foundation Limited	Pesticidal compounds
FR2676052B1 (fr) *	1991-05-02	1994-04-29	Cird Galderma	Nouveaux composes polycycliques aromatiques et leur utilisation en medecine humaine ou veterinaire et en cosmetique.
US5770382A (en) *	1994-12-30	1998-06-23	Ligand Pharmaceuticals, Inc.	Tricyclic retinoids, methods for their production and use
FR2741876B1 (fr) *	1995-12-01	1998-01-09	Cird Galderma	Composes biaromatiques portant un groupement adamantyl en para, compositions pharmaceutiques et cosmetiques les contenant et utilisations
US5888432A (en) *	1996-12-23	1999-03-30	Corning Incorporated	2-Adamantyl benzopyrans the compositions and (co)polymer matrices containing them
US5919970A (en) *	1997-04-24	1999-07-06	Allergan Sales, Inc.	Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity

1997
- 1997-07-08 IL IL12794697A patent/IL127946A0/xx unknown
- 1997-07-08 CZ CZ9934A patent/CZ3499A3/cs unknown
- 1997-07-08 CA CA002259936A patent/CA2259936C/en not_active Expired - Fee Related
- 1997-07-08 US US09/214,422 patent/US6127415A/en not_active Expired - Fee Related
- 1997-07-08 RU RU99102174/14A patent/RU2209626C2/ru not_active IP Right Cessation
- 1997-07-08 NZ NZ333800A patent/NZ333800A/xx unknown
- 1997-07-08 CN CNB971977437A patent/CN1279902C/zh not_active Expired - Fee Related
- 1997-07-08 HU HU9903834A patent/HUP9903834A3/hu unknown
- 1997-07-08 AU AU36485/97A patent/AU719311B2/en not_active Ceased
- 1997-07-08 EP EP97933256A patent/EP0920312B1/de not_active Expired - Lifetime
- 1997-07-08 DE DE69731885T patent/DE69731885T2/de not_active Expired - Lifetime
- 1997-07-08 WO PCT/US1997/011564 patent/WO1998001132A1/en not_active Ceased
- 1997-07-08 ES ES97933256T patent/ES2231877T3/es not_active Expired - Lifetime
- 1997-07-08 AT AT97933256T patent/ATE284213T1/de active
- 1997-07-08 JP JP10505270A patent/JP2000515506A/ja not_active Ceased
- 1997-07-08 TR TR1999/00684T patent/TR199900684T2/xx unknown
- 1997-07-08 PT PT97933256T patent/PT920312E/pt unknown
- 1997-07-08 BR BR9710255A patent/BR9710255A/pt not_active Application Discontinuation
1999
- 1999-01-07 NO NO990066A patent/NO990066L/no unknown
- 1999-01-08 KR KR1019997000075A patent/KR20000023626A/ko not_active Ceased
- 1999-02-05 BG BG103152A patent/BG103152A/xx unknown

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1997003682A1 (en) *	1995-07-17	1997-02-06	Centre International De Recherches Dermatologiques C.I.R.D. Galderma	Method for treating cancers using 6-[3-[1-adamantyl]-4-hydroxyphenyl]

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHARPENTIER B ET AL: "SYNTHESIS, STRUCTURE-AFFINITY RELATIONSHIPS, AND BIOLOGICAL ACTIVITIES OF LIGANDS BINDING TO RETINOIC ACID RECEPTOR SUBTYPES", JOURNAL OF MEDICINAL CHEMISTRY,US,AMERICAN CHEMICAL SOCIETY. WASHINGTON, vol. 38, no. 26, 22 December 1995 (1995-12-22), pages 4995 - 5006, XP002026831, ISSN: 0022-2623 *
SCHADENDORF D ET AL: "RETINOIC ACID RECEPTOR-GAMMA-SELECTIVE RETINOIDS EXERT ANTIPORLIFERATIVE EFFECTS ON HUMAN MELANOMA CELL GROWTH IN VITRO", INTERNATIONAL JOURNAL OF ONCOLOGY,GR,EDITORIAL ACADEMY OF THE INTERNATIONAL JOURNAL OF ONCOLOGY,, vol. 5, no. 6, 1 December 1994 (1994-12-01), pages 1325 - 1331, XP000600684, ISSN: 1019-6439 *
SHAO Z -M ET AL: "P53 INDEPENDENT G0/G1 ARREST AND APOPTOSIS INDUCED BY A NOVEL RETINOID IN HUMAN BREAST CANCER CELLS", ONCOGENE,GB,BASINGSTOKE, HANTS, vol. 11, no. 3, 3 August 1995 (1995-08-03), pages 493 - 504, XP000575582, ISSN: 0950-9232 *

Also Published As

Publication number	Publication date
WO1998001132A1 (en)	1998-01-15
PT920312E (pt)	2005-04-29
TR199900684T2 (xx)	1999-07-21
AU3648597A (en)	1998-02-02
HUP9903834A2 (hu)	2000-05-28
BG103152A (bg)	1999-09-30
CN1279902C (zh)	2006-10-18
ES2231877T3 (es)	2005-05-16
AU719311B2 (en)	2000-05-04
BR9710255A (pt)	1999-08-10
DE69731885D1 (de)	2005-01-13
CA2259936A1 (en)	1998-01-15
CA2259936C (en)	2009-02-03
JP2000515506A (ja)	2000-11-21
CZ3499A3 (cs)	1999-11-17
RU2209626C2 (ru)	2003-08-10
HUP9903834A3 (en)	2001-02-28
NO990066D0 (no)	1999-01-07
NO990066L (no)	1999-03-08
IL127946A0 (en)	2000-02-17
KR20000023626A (ko)	2000-04-25
EP0920312B1 (de)	2004-12-08
NZ333800A (en)	2000-08-25
EP0920312A1 (de)	1999-06-09
US6127415A (en)	2000-10-03
ATE284213T1 (de)	2004-12-15
DE69731885T2 (de)	2005-12-22
CN1230111A (zh)	1999-09-29

Legal Events

Date	Code	Title	Description
1999-04-23	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
1999-06-09	17P	Request for examination filed	Effective date: 19990114
1999-06-09	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
1999-08-25	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: GALDERMA RESEARCH & DEVELOPMENT, S.N.C.
2000-11-02	A4	Supplementary search report drawn up and despatched	Effective date: 20000919
2000-11-02	AK	Designated contracting states	Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
2000-11-02	RIC1	Information provided on ipc code assigned before grant	Free format text: 7A 61K 31/36 A, 7A 61K 31/34 B, 7A 61K 31/495 B, 7A 61K 31/70 B
2002-04-24	17Q	First examination report despatched	Effective date: 20020311
2003-08-20	RIC1	Information provided on ipc code assigned before grant	Ipc: 7A 61P 35/00 B Ipc: 7A 61K 31/70 B Ipc: 7A 61K 31/495 B Ipc: 7A 61K 31/34 B Ipc: 7A 61K 31/36 A
2003-08-27	RIC1	Information provided on ipc code assigned before grant	Ipc: 7A 61P 35/00 B Ipc: 7A 61K 31/70 B Ipc: 7A 61K 31/495 B Ipc: 7A 61K 31/34 B Ipc: 7A 61K 31/36 A
2004-03-19	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2004-09-29	GRAS	Grant fee paid	Free format text: ORIGINAL CODE: EPIDOSNIGR3
2004-10-22	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2004-12-08	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
2004-12-08	REG	Reference to a national code	Ref country code: GB Ref legal event code: FG4D
2004-12-15	REG	Reference to a national code	Ref country code: CH Ref legal event code: EP
2005-01-12	REG	Reference to a national code	Ref country code: IE Ref legal event code: FG4D
2005-01-13	REF	Corresponds to:	Ref document number: 69731885 Country of ref document: DE Date of ref document: 20050113 Kind code of ref document: P
2005-01-25	REG	Reference to a national code	Ref country code: SE Ref legal event code: TRGR
2005-03-15	REG	Reference to a national code	Ref country code: CH Ref legal event code: NV Representative=s name: R. A. EGLI & CO. PATENTANWAELTE
2005-03-28	REG	Reference to a national code	Ref country code: GR Ref legal event code: EP Ref document number: 20050400356 Country of ref document: GR
2005-04-11	REG	Reference to a national code	Ref country code: DK Ref legal event code: T3
2005-04-29	REG	Reference to a national code	Ref country code: PT Ref legal event code: SC4A Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20050210
2005-05-16	REG	Reference to a national code	Ref country code: ES Ref legal event code: FG2A Ref document number: 2231877 Country of ref document: ES Kind code of ref document: T3
2005-08-01	NLR4	Nl: receipt of corrected translation in the netherlands language at the initiative of the proprietor of the patent
2005-10-14	PLBE	No opposition filed within time limit	Free format text: ORIGINAL CODE: 0009261
2005-10-14	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT
2005-11-11	ET	Fr: translation filed
2005-11-30	26N	No opposition filed	Effective date: 20050909
2007-06-15	REG	Reference to a national code	Ref country code: CH Ref legal event code: PFA Owner name: GALDERMA RESEARCH & DEVELOPMENT Free format text: GALDERMA RESEARCH & DEVELOPMENT, S.N.C.#635, ROUTE DES LUCIOLES, SOPHIA ANTIPOLIS#06560 VALBONNE (FR) -TRANSFER TO- GALDERMA RESEARCH & DEVELOPMENT#635 ROUTE DES LUCIOLES SOPHIA-ANTIPOLIS#06560 VALBONNE (FR) Ref country code: CH Ref legal event code: PFA Owner name: GALDERMA RESEARCH & DEVELOPMENT Free format text: GALDERMA RESEARCH & DEVELOPMENT#635 ROUTE DES LUCIOLES SOPHIA-ANTIPOLIS#06560 VALBONNE (FR) -TRANSFER TO- GALDERMA RESEARCH & DEVELOPMENT#LES TEMPLIERS 2400 ROUTE DES COLLES#06410 BIOT (FR)
2007-06-22	REG	Reference to a national code	Ref country code: FR Ref legal event code: CA
2011-07-29	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: GR Payment date: 20110610 Year of fee payment: 15 Ref country code: MC Payment date: 20110629 Year of fee payment: 15
2011-08-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: LU Payment date: 20110718 Year of fee payment: 15
2011-10-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: DK Payment date: 20110712 Year of fee payment: 15 Ref country code: IE Payment date: 20110712 Year of fee payment: 15 Ref country code: CH Payment date: 20110712 Year of fee payment: 15 Ref country code: FR Payment date: 20110727 Year of fee payment: 15
2011-11-30	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: AT Payment date: 20110628 Year of fee payment: 15 Ref country code: GB Payment date: 20110706 Year of fee payment: 15 Ref country code: PT Payment date: 20110707 Year of fee payment: 15 Ref country code: SE Payment date: 20110712 Year of fee payment: 15 Ref country code: DE Payment date: 20110706 Year of fee payment: 15 Ref country code: FI Payment date: 20110712 Year of fee payment: 15 Ref country code: ES Payment date: 20110817 Year of fee payment: 15
2011-12-30	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: BE Payment date: 20110712 Year of fee payment: 15 Ref country code: IT Payment date: 20110728 Year of fee payment: 15 Ref country code: NL Payment date: 20110715 Year of fee payment: 15
2013-01-15	REG	Reference to a national code	Ref country code: PT Ref legal event code: MM4A Free format text: LAPSE DUE TO NON-PAYMENT OF FEES Effective date: 20130108
2013-01-31	BERE	Be: lapsed	Owner name: GALDERMA RESEARCH & DEVELOPMENT S.N.C. Effective date*: 20120731
2013-02-13	REG	Reference to a national code	Ref country code: NL Ref legal event code: V1 Effective date: 20130201
2013-02-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120731
2013-02-28	REG	Reference to a national code	Ref country code: CH Ref legal event code: PL
2013-03-01	REG	Reference to a national code	Ref country code: GR Ref legal event code: ML Ref document number: 20050400356 Country of ref document: GR Effective date: 20130104
2013-03-05	REG	Reference to a national code	Ref country code: SE Ref legal event code: EUG
2013-03-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: MM01 Ref document number: 284213 Country of ref document: AT Kind code of ref document: T Effective date: 20120708
2013-03-27	GBPC	Gb: european patent ceased through non-payment of renewal fee	Effective date: 20120708
2013-04-02	REG	Reference to a national code	Ref country code: DK Ref legal event code: EBP
2013-04-26	REG	Reference to a national code	Ref country code: FR Ref legal event code: ST Effective date: 20130329
2013-04-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120709 Ref country code: FI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120708 Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130201 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120731 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120731 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130201 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120708 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120731
2013-05-08	REG	Reference to a national code	Ref country code: IE Ref legal event code: MM4A
2013-05-16	REG	Reference to a national code	Ref country code: DE Ref legal event code: R119 Ref document number: 69731885 Country of ref document: DE Effective date: 20130201
2013-05-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: GR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130204 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120731 Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120708 Ref country code: PT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130108
2013-06-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120708
2013-07-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120731 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120708
2013-10-21	REG	Reference to a national code	Ref country code: ES Ref legal event code: FD2A Effective date: 20131021
2013-10-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120709
2014-05-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120708

Publication	Publication Date	Title
EP0920312A4 (de)	2000-11-02	Apoptose induzioerende adamantyl-derivate und deren verwendung als antikrebsmittel
GT199900019A (es)	2000-08-04	Formulas farmaceuticamente estables de solucion de oxaliplatino.
PT1054887E (pt)	2006-06-30	Derivados biciclicos de piridina e pirimidina como antagonistas de receptores no neuropeptido y
CO4810373A1 (es)	1999-06-30	Compuestos azapoliciclicos condensados con arilo
DE69332438D1 (de)	2002-11-28	7-halo-und 7(beta), 8(beta)-methano-taxolen, antineoplastische verwendung und diese enthaltende pharmazeutische zusammenstellungen
BG104996A (en)	2001-07-31	Indole derivatives and their use in the treatment of malignant and other diseases caused by pathological cell proliferation
NO20020960L (no)	2002-04-22	Benzyliden-tiazolidindioner og analoger og anvendelse av dem for behandling av diabetes
TR200102800T2 (tr)	2002-01-21	Yeni bileşikler.
DK0873332T3 (da)	2004-07-26	Discodermolidforbindelser samt farmaceutiske sammensætninger indeholdende dem til cancerterapi
EP1200123A4 (de)	2003-05-02	Diagnose und behandlung neurorektodermaler tumore
ATE223912T1 (de)	2002-09-15	Pyridylalkan-säureamide als cytostatika und immunosupressive arzneimittel
BR9608488A (pt)	1999-11-30	Uso de derivados da vitamina d4 no tratamento de câncer
TR200402083T2 (tr)	2004-10-21	Parkinson hastalığı, adhd ve mikroadenomların tedavisi için ilaçlar
DE60021381D1 (de)	2005-08-25	Chinonverbindungen zur behandlung von krankheiten
NO20026242L (no)	2003-02-27	Syntesemetoder for aplidin og nye antitumorale derivater, metoder for deresfremstilling og anvendelse av disse
ATE171170T1 (de)	1998-10-15	7-äther-taxol ähnliche verbindungen antineoplastische verwendung und diese enthaltende pharmazeutische zusammenstellungen
AR037343A1 (es)	2004-11-03	Uso de antagonistas del receptor de endotelina para la preparacion de un medicamento destinado al tratamiento de enfermedades tumorales
AU3029297A (en)	1998-01-05	7alpha-(5-methylaminopentyl)-estratrienes, process for their production, pharmaceutical preparations that contain these 7alpha-(5-methylaminopentyl)-estratrienes as well as their use for the production of pharmaceutical agents
Zeng et al.	1998	Design of new topoisomerase II inhibitors based upon a quinobenzoxazine self-assembly model
TR200002203T2 (tr)	2000-12-21	Lemfotoksin (LT) sentezlenme yolunun inhibitörleri kullanılarak foliküler lemfomaların tedavisi.
TR199900662T2 (xx)	1999-06-21	1-Hidroksi-2-piridonlar�n seborik dermatit tedavisi amac�yla kullan�m�
TR200200017T2 (tr)	2002-05-21	Benzofuran türevleri
EA200501568A1 (ru)	2006-06-30	8β-ВИНИЛ 11β-(ω-ЗАМЕЩЁННЫЕ)АЛКИЛЭСТРА-1,3,5(10)-ТРИЕНЫ
Okamoto et al.	2008	Novel deuterated gemini-vitamin D3 analogs have potent antitumor activity
CA2270026A1 (en)	1999-10-29	Substituted bicyclic derivatives for treating central nervous system disorders